Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, and Lactobacillus delbrueckii LDD01) in patients undergoing bowel preparation
Bowel preparation (BP) for colonoscopy induces significantly changes in gut microbiota and elicit intestinal symptoms. Impaired microbiota causes an intestinal dysbiosis. Consequently, probiotics may counterbalance the disturbed microbiota after BP. The current survey evaluated the efficacy and safe...
Gespeichert in:
Veröffentlicht in: | Acta bio-medica : Atenei Parmensis 2019-07, Vol.90 (7-S), p.13-17 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 17 |
---|---|
container_issue | 7-S |
container_start_page | 13 |
container_title | Acta bio-medica : Atenei Parmensis |
container_volume | 90 |
creator | Bonavina, Luigi Ariani, Andrea Ficano, Leonardo Iannuzziello, Domenico Pasquale, Luigi Aragona, Salvo Emanuele Drago, Lorenzo Ciprandi, Giorgio On Digestive Disorders, Italian Study Group |
description | Bowel preparation (BP) for colonoscopy induces significantly changes in gut microbiota and elicit intestinal symptoms. Impaired microbiota causes an intestinal dysbiosis. Consequently, probiotics may counterbalance the disturbed microbiota after BP. The current survey evaluated the efficacy and safety of Abincol®, an oral nutraceutical containing a probiotic mixture with Lactobacillus plantarum LP01 (1 billion of living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 millions of living cells), and Lactobacillus delbrueckii LDD01 (200 millions of living cells), in 2,979 outpatients (1,579 males and 1,400 females, mean age 56 years) undergoing BP. Patients took 1 stick/daily for 4 weeks after colonoscopy. Abincol® significantly diminished the presence and the severity of intestinal symptoms and improved stool form. In conclusion, the current survey suggests that Abincol® may be considered an effective and safe therapeutic option in the management of patients undergoing BP. |
doi_str_mv | 10.23750/abm.v90i7-S.8650 |
format | Article |
fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6776169</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31292421</sourcerecordid><originalsourceid>FETCH-LOGICAL-p181t-6bd512b9052a1cbb86150b49b0d0d3b7119735fa6494b18ac0405242dc209fd83</originalsourceid><addsrcrecordid>eNpdkFtLAzEQhYMottT-AF8kr4JbJ8kmu3kRpPUGCwrq85Jba3BvJLsVf4t_1gUvWJ-GmY9zmHMQOiawoCzjcK50vdhK8FnyuMgFhz00pZyRRGQp30dTYJImKQU2QfMYvYYUaE4Eg0M0YYRKmlIyRR-FMn2rlfFVNUTcVarpVRhqXDwAOcO7tBo3H3EcdOyc8S5iE1zdhvFWFEugZ1g19p_GukqHwZlX73GxWgE5xb7Bneq9a_qIh8a6sGl9s8G6fXMV7oLrVBhx2xyhg7Wqopt_zxl6vr56Wt4mxf3N3fKySDqSkz4R2nJCtQROFTFa54Jw0KnUYMEynREiM8bXSqQy1SRXZmyCj-mtoSDXNmczdPHl2w26dtaMjwVVlV3wtQrvZat8uUsa_1Ju2m0pskwQIUeDk78Gv8qfmtknzEOEcg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, and Lactobacillus delbrueckii LDD01) in patients undergoing bowel preparation</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Bonavina, Luigi ; Ariani, Andrea ; Ficano, Leonardo ; Iannuzziello, Domenico ; Pasquale, Luigi ; Aragona, Salvo Emanuele ; Drago, Lorenzo ; Ciprandi, Giorgio ; On Digestive Disorders, Italian Study Group</creator><creatorcontrib>Bonavina, Luigi ; Ariani, Andrea ; Ficano, Leonardo ; Iannuzziello, Domenico ; Pasquale, Luigi ; Aragona, Salvo Emanuele ; Drago, Lorenzo ; Ciprandi, Giorgio ; On Digestive Disorders, Italian Study Group</creatorcontrib><description>Bowel preparation (BP) for colonoscopy induces significantly changes in gut microbiota and elicit intestinal symptoms. Impaired microbiota causes an intestinal dysbiosis. Consequently, probiotics may counterbalance the disturbed microbiota after BP. The current survey evaluated the efficacy and safety of Abincol®, an oral nutraceutical containing a probiotic mixture with Lactobacillus plantarum LP01 (1 billion of living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 millions of living cells), and Lactobacillus delbrueckii LDD01 (200 millions of living cells), in 2,979 outpatients (1,579 males and 1,400 females, mean age 56 years) undergoing BP. Patients took 1 stick/daily for 4 weeks after colonoscopy. Abincol® significantly diminished the presence and the severity of intestinal symptoms and improved stool form. In conclusion, the current survey suggests that Abincol® may be considered an effective and safe therapeutic option in the management of patients undergoing BP.</description><identifier>ISSN: 0392-4203</identifier><identifier>EISSN: 2531-6745</identifier><identifier>DOI: 10.23750/abm.v90i7-S.8650</identifier><identifier>PMID: 31292421</identifier><language>eng</language><publisher>Italy: Mattioli 1885</publisher><subject>Original</subject><ispartof>Acta bio-medica : Atenei Parmensis, 2019-07, Vol.90 (7-S), p.13-17</ispartof><rights>Copyright: © 2019 ACTA BIO MEDICA SOCIETY OF MEDICINE AND NATURAL SCIENCES OF PARMA 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776169/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776169/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31292421$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bonavina, Luigi</creatorcontrib><creatorcontrib>Ariani, Andrea</creatorcontrib><creatorcontrib>Ficano, Leonardo</creatorcontrib><creatorcontrib>Iannuzziello, Domenico</creatorcontrib><creatorcontrib>Pasquale, Luigi</creatorcontrib><creatorcontrib>Aragona, Salvo Emanuele</creatorcontrib><creatorcontrib>Drago, Lorenzo</creatorcontrib><creatorcontrib>Ciprandi, Giorgio</creatorcontrib><creatorcontrib>On Digestive Disorders, Italian Study Group</creatorcontrib><title>Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, and Lactobacillus delbrueckii LDD01) in patients undergoing bowel preparation</title><title>Acta bio-medica : Atenei Parmensis</title><addtitle>Acta Biomed</addtitle><description>Bowel preparation (BP) for colonoscopy induces significantly changes in gut microbiota and elicit intestinal symptoms. Impaired microbiota causes an intestinal dysbiosis. Consequently, probiotics may counterbalance the disturbed microbiota after BP. The current survey evaluated the efficacy and safety of Abincol®, an oral nutraceutical containing a probiotic mixture with Lactobacillus plantarum LP01 (1 billion of living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 millions of living cells), and Lactobacillus delbrueckii LDD01 (200 millions of living cells), in 2,979 outpatients (1,579 males and 1,400 females, mean age 56 years) undergoing BP. Patients took 1 stick/daily for 4 weeks after colonoscopy. Abincol® significantly diminished the presence and the severity of intestinal symptoms and improved stool form. In conclusion, the current survey suggests that Abincol® may be considered an effective and safe therapeutic option in the management of patients undergoing BP.</description><subject>Original</subject><issn>0392-4203</issn><issn>2531-6745</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpdkFtLAzEQhYMottT-AF8kr4JbJ8kmu3kRpPUGCwrq85Jba3BvJLsVf4t_1gUvWJ-GmY9zmHMQOiawoCzjcK50vdhK8FnyuMgFhz00pZyRRGQp30dTYJImKQU2QfMYvYYUaE4Eg0M0YYRKmlIyRR-FMn2rlfFVNUTcVarpVRhqXDwAOcO7tBo3H3EcdOyc8S5iE1zdhvFWFEugZ1g19p_GukqHwZlX73GxWgE5xb7Bneq9a_qIh8a6sGl9s8G6fXMV7oLrVBhx2xyhg7Wqopt_zxl6vr56Wt4mxf3N3fKySDqSkz4R2nJCtQROFTFa54Jw0KnUYMEynREiM8bXSqQy1SRXZmyCj-mtoSDXNmczdPHl2w26dtaMjwVVlV3wtQrvZat8uUsa_1Ju2m0pskwQIUeDk78Gv8qfmtknzEOEcg</recordid><startdate>20190710</startdate><enddate>20190710</enddate><creator>Bonavina, Luigi</creator><creator>Ariani, Andrea</creator><creator>Ficano, Leonardo</creator><creator>Iannuzziello, Domenico</creator><creator>Pasquale, Luigi</creator><creator>Aragona, Salvo Emanuele</creator><creator>Drago, Lorenzo</creator><creator>Ciprandi, Giorgio</creator><creator>On Digestive Disorders, Italian Study Group</creator><general>Mattioli 1885</general><scope>NPM</scope><scope>5PM</scope></search><sort><creationdate>20190710</creationdate><title>Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, and Lactobacillus delbrueckii LDD01) in patients undergoing bowel preparation</title><author>Bonavina, Luigi ; Ariani, Andrea ; Ficano, Leonardo ; Iannuzziello, Domenico ; Pasquale, Luigi ; Aragona, Salvo Emanuele ; Drago, Lorenzo ; Ciprandi, Giorgio ; On Digestive Disorders, Italian Study Group</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p181t-6bd512b9052a1cbb86150b49b0d0d3b7119735fa6494b18ac0405242dc209fd83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bonavina, Luigi</creatorcontrib><creatorcontrib>Ariani, Andrea</creatorcontrib><creatorcontrib>Ficano, Leonardo</creatorcontrib><creatorcontrib>Iannuzziello, Domenico</creatorcontrib><creatorcontrib>Pasquale, Luigi</creatorcontrib><creatorcontrib>Aragona, Salvo Emanuele</creatorcontrib><creatorcontrib>Drago, Lorenzo</creatorcontrib><creatorcontrib>Ciprandi, Giorgio</creatorcontrib><creatorcontrib>On Digestive Disorders, Italian Study Group</creatorcontrib><collection>PubMed</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Acta bio-medica : Atenei Parmensis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bonavina, Luigi</au><au>Ariani, Andrea</au><au>Ficano, Leonardo</au><au>Iannuzziello, Domenico</au><au>Pasquale, Luigi</au><au>Aragona, Salvo Emanuele</au><au>Drago, Lorenzo</au><au>Ciprandi, Giorgio</au><au>On Digestive Disorders, Italian Study Group</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, and Lactobacillus delbrueckii LDD01) in patients undergoing bowel preparation</atitle><jtitle>Acta bio-medica : Atenei Parmensis</jtitle><addtitle>Acta Biomed</addtitle><date>2019-07-10</date><risdate>2019</risdate><volume>90</volume><issue>7-S</issue><spage>13</spage><epage>17</epage><pages>13-17</pages><issn>0392-4203</issn><eissn>2531-6745</eissn><abstract>Bowel preparation (BP) for colonoscopy induces significantly changes in gut microbiota and elicit intestinal symptoms. Impaired microbiota causes an intestinal dysbiosis. Consequently, probiotics may counterbalance the disturbed microbiota after BP. The current survey evaluated the efficacy and safety of Abincol®, an oral nutraceutical containing a probiotic mixture with Lactobacillus plantarum LP01 (1 billion of living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 millions of living cells), and Lactobacillus delbrueckii LDD01 (200 millions of living cells), in 2,979 outpatients (1,579 males and 1,400 females, mean age 56 years) undergoing BP. Patients took 1 stick/daily for 4 weeks after colonoscopy. Abincol® significantly diminished the presence and the severity of intestinal symptoms and improved stool form. In conclusion, the current survey suggests that Abincol® may be considered an effective and safe therapeutic option in the management of patients undergoing BP.</abstract><cop>Italy</cop><pub>Mattioli 1885</pub><pmid>31292421</pmid><doi>10.23750/abm.v90i7-S.8650</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0392-4203 |
ispartof | Acta bio-medica : Atenei Parmensis, 2019-07, Vol.90 (7-S), p.13-17 |
issn | 0392-4203 2531-6745 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6776169 |
source | EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
subjects | Original |
title | Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, and Lactobacillus delbrueckii LDD01) in patients undergoing bowel preparation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T01%3A05%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lactobacillus%20plantarum%20LP01,%20Lactobacillus%20lactis%20subspecies%20cremoris%20LLC02,%20and%20Lactobacillus%20delbrueckii%20LDD01)%20in%20patients%20undergoing%20bowel%20preparation&rft.jtitle=Acta%20bio-medica%20:%20Atenei%20Parmensis&rft.au=Bonavina,%20Luigi&rft.date=2019-07-10&rft.volume=90&rft.issue=7-S&rft.spage=13&rft.epage=17&rft.pages=13-17&rft.issn=0392-4203&rft.eissn=2531-6745&rft_id=info:doi/10.23750/abm.v90i7-S.8650&rft_dat=%3Cpubmed%3E31292421%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31292421&rfr_iscdi=true |